(CHRS) - Earnings & Price History

CHRS: - 11.2, $593.05M, -0.05 (-0.44%)

Sector: Healthcare - Industry: Biotechnology

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companys product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis, as well as to treat ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis; and CHS-5217, a bevacizumab biosimilar candidate to treat metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate to treat ankylosi

Past CHRS reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-13AMC-1.1122.17523.4522.221.223.025-5.33%-0.11%-5.44%955.64K
2016-11-09AMC-1.5227.9527.126.2523.2529.55-3.14%▲6.48%3.14%1.09M
2016-08-09AMC-1.3229.0429.729.7327.2330.50.10%-2.32%-2.22%462.98K
2016-05-09AMC-1.421819.218.8215.0419.17-1.98%-4.36%-6.25%1.21M
2016-02-29AMC15.0214.1913.8513.1215.03-2.40%8.45%5.85%274.61K
2015-08-10AMC33.1533.873431.58340.38%-2.50%-2.13%670.62K
2015-03-23AMC-0.6427.1825.628.6273011.72%-4.97%6.17%498.03K
2014-12-15AMCCoherus Biosc-1.7913.6313.7813.8213.1914.470.29%▲-1.37%-1.09%215.20K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades